Podcasts about Imaging

This time on Naked Neuroscience, James Tytko explores the miracle of magnetic resonance imaging (MRI) with Stephanie Brown from the University of Cambridge, including a new innovation to decrease 'scan-xiety' amongst children. Then, we'll be investigating the complexities of the current youth mental health crisis, with the help of Susanne Schweizer and Camilla Nord... Like this podcast? Please help us by supporting the Naked Scientists

Ana Rosa, MD, PhD is a physician, Radiologist, Body fellowship trained, alumni of the University of Minnesota, medical doctor at the VA healthcare system, and assistant professor at the University of Minnesota. Dr. Rosa has done two radiology residencies, one in Brazil, and one in the United States, obtained a doctorate degree, had done a body imaging fellowship, and also has published in medical journals and helped writing Imaging books in Brazil with 25 years of practice in the Imaging field as a Radiologist. Dr. Rosa shares with us her imaging knowledge of visceral fat, the importance of its detection and description in the reports, guiding the patients and the ordering providers by the findings on cross-section imaging such as MRI scans.  The podcast intention is to bring awareness on how to detect a simple and easy biomarker such as visceral fat on MRI scans making it easier for patients to advocate for health and follow up for results. Dr. Rosa shares with us how to create quality of care in service for education and interaction between patients, providers and Radiologists in sharing her own story on how to heal from inside out by literally “seeing” a “silent” metabolic active killer that visceral fat represents and taking action to change the presence status quo And move towards optimizing health.     SHOW NOTES (06:37) In medical school, healthcare professionals are trained to describe diseases while overlooking how visceral fat and metabolic health contributes to them. (15:52) Visceral fat is a major culprit when it comes to various metabolic issues. (28:04) The first step to prevent disease is to look for signs of inflammation. (31:17) While it's possible to request your MRI scan from your doctor, most providers won't know how to make use of it. (44:02) Health is not limited to staying alive. Health is also appearance and performance. (53:58) For doctors, another benefit of learning to deal with patients carrying high amounts of visceral fat is potentially minimizing burnout.

Guest host Dr. Gagandeep Choudhary summarizes the article “Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and Molecular Imaging” focusing on pathophysiology and imaging findings of some of the major neurodegenerative processes.  Multimodality Imaging of Demen-tia: Clinical Importance and Role of Integrated Anatomic and Mo-lecular Imaging. Patel et al. RadioGraphics 2020; 40:200–222.

It's Live Imaging Tuesday! Mason and Ireland are joined by Morales today and the guys go over their Thanksgiving plans. Why are there two turkeys at the Ireland residence? Mason shares a Thanksgiving story from when he was a kid. Mychal Thompson joins the guys in the studio today! Ramona Shelburne drops by the studio as well today! The guys dive into the LaMelo Ball story around his neck tattoo and his clothing brand. Wheel of Questions! Learn more about your ad choices. Visit megaphone.fm/adchoices

Juan Lopez-Mattei is Medical Director and Director of Cardiac Imaging, Lee Health Heart & Vascular Institute, Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS) https://pubmed.ncbi.nlm.nih.gov/36216699/

Commentary by Dr. Valentin Fuster

Imaging of: Radicular (Periapical Cyst) Dentigerous Cyst Odontogenic Keratocyst Ameloblastoma

CONTENT WARNING: Depictions of police corruption and gun violence, character betrayal, paranoia, and loud noises. 02052020: As fresh obstacles present themselves at the Oslow site, a new lead spins the investigation in an unexpected direction. Starring Leah Booth as dispatch, Mike Kennedy as Edgar Morrison, Zane Schacht as Seb Jenkins, B. Narr as Drone Control, Josh Beard as Coordination, Athena Lee as Imaging, Mike LeBeau as Security, Dontae Majors as Sensors, Kris Allison as Dana Caldwell, Brandon Jenkins as Transport, Van Winkle as Sam Bailey, Ezra J. Wayne as Ned Leroux, Virginia Spotts as Kate Sheridan, Sam Taylor as Ren Park, and Amitola Lomas as Maria Sol, with original music by Jesse Haugen. Written by Van Winkle and produced by Virginia Spotts, with dialogue editing and sound design by Van Winkle. This episode was made possible by our supporters at Patreon.com/homesteadcorner, ko-fi.com/homesteadcorner, and our backers on Seed&Spark. For more information, additional content, and episode transcript, visit homesteadonthecorner.com/tst082 Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Gaitonde and Dr. Fares share about advanced imaging for fetal heart patients and how this innovative technology can help diagnose fetal heart conditions and inform treatment for critical, postnatal interventions.

Klamath Falls archeologist Dan Broockmann, and Ken Sandusky of the Modoc Tribe talk about efforts to "image" archaeological sites, so that Modoc Nation members in Oklahoma can "experience" their ancestral homelands.

The introduction of weight-bearing CT scans has revolutionized how surgeons assess and treat various orthopedic conditions. Research indicates this technology can provide clinicians with in-depth, real-time insights, allowing for better patient outcomes and more accurate diagnoses.How is weight bearing CT technology influencing the approach of orthopedic surgeons, and how are patients benefitting from it?Welcome to the CurveBeam AI Cast, where the future of orthopedics is at the forefront. In this episode, hosted by Dr. Lew Schon, a renowned Orthopedic Surgeon and Director of Innovation at Mercy Medical Center and Professor at John Hopkins University and NYU Langone, examines the impact of weight bearing CT imaging in a typical orthopedic clinic with his guest Dr. Blake Moore, an experienced Orthopedic Surgeon from Virginia Beach, who shares his journey with this innovative technology.Key conversation points include:• The evolution and early adoption of weight bearing CT scans• The physiological benefits of assessing limbs under actual weight bearing conditions• How the imaging precision of weight bearing CT scans influences surgical decision-makingDr. Blake Moore, originally from Albany, New York, completed his medical studies at Albany Medical College before undertaking his residency at Geisinger Medical Center in Pennsylvania. Following a fellowship with Paul Giuliano at Penn State, Dr. Moore has spent almost a decade in Virginia, using weight bearing CT scans in his practice and advocating for its broader implementation. His commitment to advancing orthopedics through technology and research is evident in his work and collaborative efforts with fellow professionals.

In this episode of Design World's Technology Tuesdays Podcast, VP, Editorial Director Paul J. Heney chats about vision systems with Philip Freidin, an Applications Engineer with IDS Imaging Development Systems Inc. They discuss new and interesting applications, how to select the best industrial camera system, and what the future holds for this important technology area.

Interview with Gary Agnew, CEO, Co-Founder and Director of IDEON TechnologiesRecording date: 7th November 2023Overview of IDEON's Novel Subsurface Imaging TechnologyIDEON Technologies utilizes a new subsurface imaging technique called muon tomography to help mining companies precisely locate ore deposits and optimize extraction. As explained by CEO GA, muon tomography functions analogously to medical imaging like X-rays or CT scans. It provides a high-resolution 3D model of density variations underground by detecting muons, subatomic particles that constantly bombard Earth.This technology enables accurate identification and pinpoint localization of mineral deposits and anomalies. In an initial blind trial validation process, IDEON delivers density models for a test area based solely on its muon scanning, while the client provides drill hole data. Matching IDEON's imaging against hundreds of historical drill results establishes accuracy and builds confidence.Transition to Multi-Year Commercial RelationshipsAfter successful blind trials, IDEON transitions clients like BHP and Glencore to multi-year subscription contracts. The company handles all hardware, software, communications, analysis, and data delivery, providing a streamlined “full stack solution.” This simplifies adoption for the mining company and reduces contractual risks.Importantly, IDEON does not take equity positions or seek royalties based on resource value unlocked. The company focuses entirely on providing premium subsurface imaging capabilities as an excellent technology partner. Its goal is recurring revenue growth through long-term subscription clients, not competing with or threatening the core business of miners.Current Commercial TractionIDEON now has 8 major mining companies as active clients. All have progressed beyond initial blind testing. The company is expanding adoption site-by-site with each customer.While starting in greenfield exploration, IDEON currently focuses on brownfield exploration and active mining operations. Its data integrates with and enhances legacy gravity, electromagnetic, and seismic data sets through multiphysics inversion. This leverages prior mining investments while providing new, high-value insights.Unlocking Substantial Value for MinersBy optimizing drilling programs, IDEON reduces clients' largest operational cost. More accurate targeting also increases ore recovery while leaving waste rock undisturbed. This boosts profitability and minimizes environmental impacts.Further, faster discovery and analysis accelerates the timeline from initial exploration to production for in-demand resources. With explosive demand growth projected for critical minerals like copper and cobalt, unlocking supply faster creates immense value.Introduction to IDEON's Novel Subsurface Imaging TechnologyMuon tomography provides 3D mineral density data, like medical CT scansBlind trials validate accuracy against hundreds of drill hole resultsTransition to Multi-Year Commercial RelationshipsAfter trials, clients adopt multi-year subscription modelFocus is excellent technology service, not competing with clientsCurrent Commercial Traction8 major mining companies now active clients beyond trialsExpanding adoption site-by-site with each existing customerUnlocking Substantial Value for MinersOptimizing drilling investment, improving targetingIncreasing ore recovery, decreasing waste rockAccelerating discovery-to-production timelineGrowth Prospects and Market PotentialWhile currently focused on brownfield and active mine sites, CEO GA noted muon tomography could provide value across the entire mining lifecycle. IDEON takes a customer-centric approach to identifying the most critical problems to solve across exploration, development, and production.Rather than seeking a percentage of the immense potential value unlocked, IDEON believes its contribution merits a reasonable premium price point. Maintaining commercial pragmatism and partnerships will enable growth.If IDEON can leverage its innovative technology to optimize mining operations, unlock supply of key mineral resources, and scale customer adoption through a value-focused approach, the company may present a compelling investment opportunity. Subsurface imaging capabilities that accelerate discovery and extraction of critical minerals could prove valuable for mining companies and decarbonization efforts alike.Learn more: https://cruxinvestor.comSign up for Crux Investor: https://cruxinvestor.com

In this episode we are joined by Jan Makela, President & CEO of Imaging at GE HealthCare who discusses the critical shortage of radiologists and its potential impact on healthcare. Tune in to gain insights on how organizations are leveraging technology to address challenges in radiology today. This episode is sponsored by GE HealthCare.

Lobular breast cancer is cancer that starts in the lobules, the glands in the breast that produce milk. Lobular breast cancer is the second most common breast cancer, accounting for about 10% of breast cases in the United States. Lobular breast cancer doesn't always form a lump and can spread to areas of the body different from ductal breast cancer, such as the abdominal lining or the tissue around the kidneys or the eyes. Listen to the podcast to hear Dr. Jochelson explain: why lobular breast cancer is harder to see on mammograms the imaging tests used to figure out if lobular breast cancer has spread to other areas of the body the difference between a FES PET scan and a FDG PET scan

Support Joshua for President at https://JoshuaSmith2024.com Join the patreon at https://patreon.com/breakthecyclejs Join Subscribestar at https://Subscribestar.com/breakthecyclejs Tips at https://paypal.me/JoshuaSmithChair2020 available on all of your favorite podcast apps. https://toplobsta.com for dope gear. https://AnthemPlanning.com for all your emergency and crisis planning needs. thank you to Whiskey Grenade for the great jams. Support the stream: https://streamlabs.com/fightthedespots Welcome Music from Uppbeat (free for Creators!): https://uppbeat.io/t/mood-maze/cybertruck License code: T8XU7DW6MON5ASB9 --- Support this podcast: https://podcasters.spotify.com/pod/show/breakthecycle/support

Guest host Dr. Shahriar Faghani talks about an article published in the journal entitled Translating AI to Clinical Practice: Overcoming Data Shift with Explainability. Translating AI to Clinical Practice:Overcoming Data Shift with Explainability. Choi et al. RadioGraphics 2023; 43(5):e220105.

  Michael Hofman, LuTectom, Violet and more theranostics for Prostate cancer Prof Michal Hofman from Peter Mac talks to us about new theranostics in prostate cancer @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}  nuccast,NIF,UOM,nuclearmedicine,theranostics,cancer,radioactive,mbciu, ,nuclearmedicine,theranostics,cancer,radioactive,mbciu,PET,Petermac,prostate @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Michael Hofman, LuTectom, Violet and more theranostics for Prostate cancer Prof Michal Hofman from Peter Mac talks to us about new theranostics in prostate cancer @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}  nuccast,NIF,UOM,nuclearmedicine,theranostics,cancer,radioactive,mbciu, ,nuclearmedicine,theranostics,cancer,radioactive,mbciu,PET,Petermac,prostate @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Michael Hofman, LuTectom, Violet and more theranostics for Prostate cancer Prof Michal Hofman from Peter Mac talks to us about new theranostics in prostate cancer @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}  nuccast,NIF,UOM,nuclearmedicine,theranostics,cancer,radioactive,mbciu, ,nuclearmedicine,theranostics,cancer,radioactive,mbciu,PET,Petermac,prostate @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

  Michael Hofman, LuTectom, Violet and more theranostics for Prostate cancer Prof Michal Hofman from Peter Mac talks to us about new theranostics in prostate cancer @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}  nuccast,NIF,UOM,nuclearmedicine,theranostics,cancer,radioactive,mbciu, ,nuclearmedicine,theranostics,cancer,radioactive,mbciu,PET,Petermac,prostate @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

Dr. Rogan Magee discusses Dopamine Transporter (DAT) Imaging.

On today's episode, we will be discussing the newly released DJI Osmo Pocket 3. It's amazing to see how DJI continues to raise the bar with its Osmo range, from the OSMO Pocket to the Pocket 2 and now to the Pocket 3. The new model features a bigger sensor, a bigger screen, and longer-lasting quick charging. What more could you want from a pocket-sized device? During the episode, we will briefly examine the history of the DJI Osmo Pocket, discussing its features and what makes it stand out. We will also cover the new features of the Pocket 3, which are game-changers. Before buying the Osmo Pocket 3, we recommend listening to this episode. You might be surprised by what you learn.

Where does imaging sit in managing our risk? In our next episode of RiskBites, Dr Annalene Weston and Dr Kiran Keshwara from Dental Protection discuss the place of imaging in dentistry. Images, whether they are x-rays, photos or digital scans, make an important part of the patient records and should be considered to be a useful adjunct to our written records. Listen to find out more about this key topic in dentistry.

Host Dr. Refky Nicola summarizes a recent review article from RadioGraphics. Find out how to stand out from the crowd and create your own outstanding exhibit.  Creating an Award-winning RSNA Education Exhibit. Albasha and Burkett et al. RadioGraphics 2022; 42:E106-E108.

Chris sat down with Marc Surdyka to address common imaging myths. We dive into 5 common myths surrounding imaging including: Imaging showing the cause of pain, imaging predicting outcomes, if you fix the image, you fix the pain, imaging dictates rehab, and imaging never matters.  Watch the full episode: https://youtu.be/suyN2b23Oj4  More on this topic:  E3 Blog on Imaging E3 YouTube Video on Imaging  --- Follow Us: YouTube: https://www.youtube.com/e3rehab  Instagram: https://www.instagram.com/e3rehab/ Twitter: https://twitter.com/E3Rehab --- Rehab & Performance Programs: https://store.e3rehab.com/  Newsletter: https://e3rehab.ck.page/19eae53ac1  Coaching & Consultations: https://e3rehab.com/coaching/  Articles: https://e3rehab.com/articles/  Apparel: https://store.e3rehab.com/collections/frontpage  --- Podcast Sponsor: Vivo Barefoot: Get 15% off all shoes! - https://www.vivobarefoot.com/e3rehab --- @dr.surdykapt @tony.comella @chrishughen --- This episode was produced by Matt Hunter.

Do you know which high-resolution computed tomography (HRCT) patterns are associated with fibrosing interstitial lung disease and its progression? Credit available for this activity expires: 10/24/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/995581?ecd=bdc_podcast_libsyn_mscpedu

Commentary by Dr. Valentin Fuster

Using math to improve photographs, with expert guest Gordon Wetzstein. Such methods have exploded in recent years and have wide-ranging impacts from improving your family photos, to making self-driving cars safer, to building ever-more-powerful microscopes. Somewhere in between hardware and software, he says, is the field of computational imaging, which makes cameras do some pretty amazing things. Wetzstein and host Russ Altman bring it all into focus on this episode of Stanford Engineering's The Future of Everything podcast.Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads or Twitter/XConnect with School of Engineering >>> Twitter/XChapters:(00:00:00) Introductions Host Russ Altman introduces the guest, Gordon Wetzstein as well as the concept of non-line-of-sight imaging.(00:02:58) Computational Imaging Gordon Wetzstein explains the concept of computational imaging and the way it integrates hardware and software for optimal image capture.(00:04:22) High Dynamic Range (HDR) Imaging  & Focal StackingAn explanation of what HDR is and how it captures high-contrast scenes, and the similar process of focal stacking, using multiple images to create depth. (00:09:56) Non-Line-of-Sight Imaging (00:15:51) Optical Computing: Extending Hardware Capabilities Insights into optical computing, explaining how specially designed hardware can preprocess data for AI algorithms.(00:18:08) Applications of Optical Computing Exploration of applications for optical computing in power constraint systems and increased efficiency in data centers.(00:23:07) The Intersection of AI, Physics, and Computer Graphics Synergy between AI, physics, and computer graphics in creating 3D content and models. (00:25:47) Generative AI to Create 3D from 2D Exploring the challenge of generating 3D digital humans from unstructured 2D images using algorithms(00:32:02) Challenges & Advancements in VR and AR Design 

Guest Gordon Wetzstein is an expert in using math to improve photographs. Such methods have exploded in recent years and have wide-ranging impacts from improving your family photos, to making self-driving cars safer, to building ever-more-powerful microscopes. Somewhere in between hardware and software, he says, is the field of computational imaging, which makes cameras do some pretty amazing things. Wetzstein and host Russ Altman bring it all into focus on this episode of Stanford Engineering's The Future of Everything podcast.

The Value of Imaging Versus Physiology Guided Post PCI

Have you ever wondered how breast cancer screenings work and why they're so crucial? Do you understand the vital role of ultrasounds in diagnosis? Tune in as our hosts of Mic Check 2 learn more about SHH Imaging Services from Mammographer, Juana Beltran and Ultra Sound Technologist Judith Moore.Everything from dissecting the prerequisites for screenings and safety protocols that ensure patients' well-being to guidance on when pregnant patients should schedule their ultrasound will be discussed, and so much more!To schedule an appointment (For the Greater Houston, Tx Area):(713) 778-1300 www.offeringhope.orgTo find Mammography Services in your state:www.nationalbreastcancer.org/national-mammography-program www.offeringhope.org | @sthopehealthcare

A new MP3 sermon from Hopewell Associate Reformed Presbyterian is now available on SermonAudio with the following details: Title: Imaging God by Worship and Work Subtitle: Family Worship Speaker: James Hakim Broadcaster: Hopewell Associate Reformed Presbyterian Event: Devotional Date: 10/23/2023 Bible: Psalm 104:16-26 Length: 16 min.

With Christoph Grani & & Katja Odening, Bern University Hospital, University of Bern - Switzerland. Link to editorial Link to paper

In this episode, my guests are Mark Zuckerberg, CEO of Meta (formerly Facebook, Inc.), and his wife, Dr. Priscilla Chan, M.D., co-founder and co-CEO of the Chan Zuckerberg Initiative (CZI). We discuss how CZI plans to cure all human diseases by the end of this century by funding transformative projects and technologies at the intersection of biology, engineering, and artificial intelligence (AI). They describe their funding and development of CZI Biohubs and the progress already underway to accelerate the understanding of cell function, pathways, and disease. Then, Mark discusses social media, its impact on mental health, and new tools for online experiences. We also discuss Meta's virtual reality (VR), augmented and mixed reality tech, and how AI will soon completely transform our online and physical life experiences. This episode ought to interest anyone curious about biology, medicine, mental health, AI, and the future of technology and humanity. For the full show notes, including the episode transcript (available exclusively to Huberman Lab Premium members), please visit hubermanlab.com. Pre-sale password: HUBERMAN Thank you to our sponsors AG1: https://drinkag1.com/huberman Eight Sleep: https://eightsleep.com/huberman LMNT: https://drinklmnt.com/huberman InsideTracker: https://insidetracker.com/huberman Momentous: https://livemomentous.com/huberman The Brain Body Contract Tickets: https://www.hubermanlab.com/events Timestamps (00:00:00) Mark Zuckerberg & Dr. Priscilla Chan (00:02:15) Sponsors: Eight Sleep & LMNT; The Brain Body Contract (00:05:35) Chan Zuckerberg Initiative (CZI) & Human Disease Research (00:08:51) Innovation & Discovery, Science & Engineering (00:12:53) Funding, Building Tools & Imaging (00:17:57) Healthy vs. Diseased Cells, Human Cell Atlas & AI, Virtual Cells (00:21:59) Single Cell Methods & Disease; CELLxGENE Tool  (00:28:22) Sponsor: AG1 (00:29:53) AI & Hypothesis Generation; Long-term Projects & Collaboration (00:35:14) Large Language Models (LLMs), In Silico Experiments (00:42:11) CZI Biohubs, Chicago, New York (00:50:52) Universities & Biohubs; Therapeutics & Rare Diseases (00:57:23) Optimism; Children & Families (01:06:21) Sponsor: InsideTracker (01:07:25) Technology & Health, Positive & Negative Interactions (01:13:17) Algorithms, Clickbait News, Individual Experience (01:19:17) Parental Controls, Meta Social Media Tools & Tailoring Experience (01:24:51) Time, Usage & Technology, Parental Tools (01:28:55) Virtual Reality (VR), Mixed Reality Experiences & Smart Glasses (01:36:09) Physical Exercise & Virtual Product Development (01:44:19) Virtual Futures for Creativity & Social Interactions (01:49:31) Ray-Ban Meta Smart Glasses: Potential, Privacy & Risks (02:00:20) Visual System & Smart Glasses, Augmented Reality (02:06:42) AI Assistants & Creators, Identity Protection (02:13:26) Zero-Cost Support, Spotify & Apple Reviews, Sponsors, YouTube Feedback, Momentous, Social Media, Neural Network Newsletter Title Card Photo Credit: Mike Blabac Disclaimer

We dive into understanding why it's important to address the source, rather than changing the course of action through imaging. Could imaging delay the process of having the right treatment?

Listener feedback, oral anticoagulation in patients with ICH, an example of statistical significance but not clinical significance, and statins and diabetes are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback October 13, 2023 This Week in Cardiology Podcast   https://www.medscape.com/viewarticle/997281 -  European Heart Journal: IVI for PCI   https://doi.org/10.1093/eurheartj/ehad430 -  Elgendy Meta-analysis of Imaging in PCI:   https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.116.003700 -  ULTIMATE:   https://www.jacc.org/doi/10.1016/j.jacc.2018.09.013 -  ILUMEIN IV: https://www.nejm.org/doi/full/10.1056/NEJMoa2305861 -  OCTOBER:  https://www.nejm.org/doi/full/10.1056/NEJMoa2307770 -  Main STEP-HFpEF paper -  Letter to the Editor on Lack of Obesity Paradox  https://doi.org/10.1016/j.amjcard.2019.04.037 II. Anticoagulation in ICH Oral Anticoagulation in ICH Patients With AF: New Data   https://www.medscape.com/viewarticle/997547 -   Lancet Neuro   Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0 -   ENRICH AF letter   https://doi.org/10.1016/S0140-6736(23)02025-1 III. Million Hearts CMS 'Million Hearts' CVD Risk Reduction Model Works   https://www.medscape.com/viewarticle/997551 -   RCT JAMA IV. Statin Choice and Diabetes April 7, 2023 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/990542 -   LODESTAR Main Study -   LODESTAR Substudy You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Communication technologies can significantly improve collaboration and efficiency within interventional radiology. In today's episode, Michael Cecil dives into the ever-evolving field of radiology and the challenges in integrating different systems in radiology departments, emphasizing the need for a vendor-neutral solution to maintain revenue streams. He emphasizes the need for effective communication technologies, a collaborative healthcare approach, meticulous HIPAA compliance, and patient engagement, as well as prioritizing patient comfort in radiology equipment. Get ready for an enlightening discussion on the heart of patient-centric radiology, advocating for comfort, transparency, and collaborative healthcare practices. Click this link to the show notes, transcript, and resources: outcomesrocket.health

Imaging with ultrasound in physical therapy: What is the PT's scope of practice? A competency-based educational model and training recommendations. Whittaker JL, Ellis R, Hodges PW, et al. Br J Sports Med. 2019;53(23):1447-1453. doi:10.1136/bjsports-2018-100193 Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest Physio Network–https://www.physio-network.com/ Learn more about/Buy Erik's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by: Kevin MacLeod – incompetech.com: Mining by Moonlight Sam Roux: Spanish Jungle

Optical coherence tomography (OCT) is a powerful imaging tool used across multiple clinical disciplines. JAMA Executive Editor Gregory Curfman, MD, speaks with 2023 Lasker Award recipient James G. Fujimoto, PhD, professor of electrical engineering at MIT, about his role in developing OCT and OCT's advancements in clinical practice. Related Content: Optical Coherence Tomography—History, Evolution, and Future Prospects

Commentary by Dr. Valentin Fuster

Three stories regarding GLP-1 agonists, imaging during PCI, and the power of sham controls in procedure trials are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. FLOW Trial Positive Novo Nordisk Stops Ozempic Kidney Trial After Early Signs of Success https://www.medscape.com/s/viewarticle/997237 -  FLOW Trial – press release https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166327 II. STEP HFpEF Semaglutide Win in HFpEF With Obesity Regardless of Ejection Fraction: STEP-HFpEF https://www.medscape.com/viewarticle/997185 The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar https://www.medscape.com/viewarticle/995872 -  STEP HFpEF substudy -   STEP HFpEF main paper III. GLP-1 Agonist Adverse Effects GLP-1 Agonists Linked to Higher Risk for Rare but Serious GI Complications https://www.medscape.com/viewarticle/997128 -  GI Adverse Effects of GLP-1 Agonists  https://jamanetwork.com/journals/jama/fullarticle/2810542 IV. Imaging in PCI Intravascular Imaging in PCI: Time for a Guideline Update? https://www.medscape.com/viewarticle/995677 -  Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA https://academic.oup.com/eurheartj/article/44/38/3845/7226277 -  HEART Review of Studies of Intracoronary Imaging During PCI  https://heart.bmj.com/content/107/9/755 V. The Power of Placebo (Sham) control Hopeful Insights, No Overall HFpEF Gains From Splanchnic Nerve Ablation: REBALANCE-HF https://www.medscape.com/viewarticle/997318 -  Transvenous Right GSN Ablationin HFpEF https://doi.org/10.1016/j.jchf.2022.05.009 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net